Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency
Open Access
- 30 September 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (14) , 1013-1020
- https://doi.org/10.1056/nejm199909303411401
Abstract
The physiologic role of dehydroepiandrosterone in humans is still unclear. Adrenal insufficiency leads to a deficiency of dehydroepiandrosterone; we therefore investigated the effects of dehydroepiandrosterone replacement in patients with adrenal insufficiency. In a double-blind study, 24 women with adrenal insufficiency received in random order 50 mg of dehydroepiandrosterone orally each morning for four months and placebo daily for four months, with a one-month washout period. We measured serum steroid hormones, insulin-like growth factor I, lipids, and sex hormone–binding globulin, and we evaluated well-being and sexuality with the use of validated psychological questionnaires and visual-analogue scales, respectively. The women were assessed before treatment, after one and four months of treatment with dehydroepiandrosterone, after one and four months of placebo, and one month after the end of the second treatment period. Treatment with dehydroepiandrosterone raised the initially low serum concentrations of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, and testosterone into the normal range; serum concentrations of sex hormone–binding globulin, total cholesterol, and high-density lipoprotein cholesterol decreased significantly. Dehydroepiandrosterone significantly improved overall well-being as well as scores for depression and anxiety. For the global severity index, the mean (±SD) change from base line was –0.18±0.29 after four months of dehydroepiandrosterone therapy, as compared with 0.03±0.29 after four months of placebo (P=0.02). As compared with placebo, dehydroepiandrosterone significantly increased the frequency of sexual thoughts (P=0.006), sexual interest (P=0.002), and satisfaction with both mental and physical aspects of sexuality (P=0.009 and P=0.02, respectively). Dehydroepiandrosterone improves well-being and sexuality in women with adrenal insufficiency.Keywords
This publication has 31 references indexed in Scilit:
- The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age‐advanced men and womenClinical Endocrinology, 1998
- Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trialFertility and Sterility, 1998
- Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 1997
- Dehydroepiandrosterone (DHEA): a fountain of youth?Journal of Clinical Endocrinology & Metabolism, 1996
- Replacement of DHEA in Aging Men and WomenAnnals of the New York Academy of Sciences, 1995
- Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old menJournal of Clinical Endocrinology & Metabolism, 1994
- Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age [published erratum appears in J Clin Endocrinol Metab 1995 Sep;80(9):2799]Journal of Clinical Endocrinology & Metabolism, 1994
- Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal womenAmerican Journal of Obstetrics and Gynecology, 1993
- Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations throughout AdulthoodJournal of Clinical Endocrinology & Metabolism, 1984
- Adrenarche: A Survey of Rodents, Domestic Animals, and PrimatesEndocrinology, 1978